The Effect of Ticlopidine on Platelet Functions in Acute Myocardial Infarction

Summary

A group of 43 consecutive patients with AMI were randomized to treatment with a novel platelet inhibitor, ticlopidine, or placebo in a double blind study. Treatment was started within 12 hr after onset of precordial pain. Patients who had taken drugs with known platelet inhibitory effect prior to the onset of therapy were excluded.

Platelet survival time (PS) was measured 24–36 hr after onset of precordial pain and after 3 months of treatment in both groups. In the early phase of AMI CK-MB and ASAT were taken twice daily for estimation of infarction size. Platelet function, coagulation factors and fibrinolysis parameters were followed sequentially for 21 days and repeated after 3 months.

In the placebo group a significant reduction in PS (5.62 ± 1.63 S. D. days) was measured in the acute phase of AMI compared to PS 3 months after infarction (8.03 ± 1.20 S.D. days). In the ticlopidine group PS was normal during the acute phase (8.35 ± 1.82 S.D. days). After 3 months of treatment PS was normal in both groups. During the first two weeks after AMI significant changes in coagulation parameters and fibrinolysis indicated an increased risk of thrombosis in both groups. These parameters were unaffected by the platelet inhibitory therapy. Estimated by peak CK-MB and ASAT, infarction size was significantly reduced in the ticlopidine group.

Keywords

Platelet survival - Ticlopidine - Acute myocardial infarction

• References

• 1 Sorkin RP, Tokarsky MJ, Huber-Smith MJ, Steiger JF, MacCann DS. In vivo platelet aggregation and plasma catecholamines in acute myocardial infarction. Am Heart J 1982; 104: 1255-1261
• 2 Zahavi J, Dreyfuss F. An abnormal pattern of adenosine diphosphate induced platelet aggregation in acute myocardial infarction. Thrombos Diathes Haemorrh 1969; 21: 76-88
• 3 Packham MA. Methods for detection of hypersensitive platelets. Thromb Haemostas 1978; 40: 175-195
• 4 Knudsen JB, Gormsen J, Skagen K, Amtorp O. Changes in platelet functions, coagulation and fibrinolysis in uncomplicated cases of acute myocardial infarction. Thromb Haemostas 1980; 42: 1513-1522
• 5 Salem HH, Koutts J, Firkin BG. Circulating platelet aggregates in ischaemic heart disease and their correlation to platelet life span. Thromb Res 1980; 17: 707-711
• 6 Sobel M. Circulating platelet products in unstable angina pectoris. Circulation 1981; 61: 300-306
• 7 Chesebro JH, Fuster V, Byrne J. Improvement of shortened platelet survival half-life from the early to the late phase of myocardial infarction. Thromb Haemostas 1981; 46: 143
• 8 Maseri A, L’Abale A, Baroldi G, Chierchia S, Marzilli M, Ballestra AM, Severi S, Parodi O, Biagni A, Distante A, Pesola A. Coronary vasospasm as a possible cause of myocardial infarction. N Engl J Med 1978; 299: 1271-1277
• 9 Haerem JW. Platelet aggregates in intramyocardial vessels of patients dying suddenly and unexpectedly of coronary artery disease. Atherosclerosis 1972; 15: 199-213
• 10 Hoffman JI E, Buckberg GD. Pathophysiology of subendocardial ischaemia. Br Med J 1975; 1: 76-79
• 11 Dunn F, Soria C, Soria J, Thomaides A, Lee H, Tobelem G, Caen JP. Effet de l’administration de ticlopidine sur la fixation du fibrinogène au niveau des plaquettes. Nouv Revue Fr Hematol 1983; 25: 132-133
• 12 Ashida S, Abiko Y. Effect of ticlopidine and acetylsalicylic acid on generation of prostaglandin I₂-like substance in rat arterial tissue. Thromb Res 1978; 13: 901-908
• 13 Cattaneo M, Kinlough-Rathbone RL, Winocour PD, Packham MA, Mustard JF. Ticlopidine prolongs shortened platelet survival by inhibiting clearance of altered platelets. Fed Proc 1982; 41: 701
• 14 Wilkinson AR, Hawker RJ, Hawker LM. The influence of antiplatelet drugs on platelet survival after aortic damage or implantation of a dacron arterial prothesis. Thromb Res 1979; 15: 181-189
• 15 Panak E, Maffrand JP, Picard-Fraire C, Vallée E, Blanchard J, Ronucci R. Ticlopidine: A promise for the prevention and treatment of thrombosis and its complications. Haemostasis 1983; 13 suppl (Suppl. 01) 1-54
• 16 Gensini GF, Favilla S, Breschi C, Abbate R, Costanzo G, Serneri GG N. Ticlopidine activity on platelet function in patients with enchanged platelet aggregation. A short-term crossover study Haemostasis 1983; 13: 294-300
• 17 Fox KM, Jonathan A, Selwyn A. Effects of platelet inhibition on myocardial ischaemia. Lancet 1982; 2: 727-730
• 18 WHO: Ischaemic Heart Disease Register. Copenhagen: Euro 1970. 51 4
• 19 Thakur ML, Welch MJ, Joist JH, Coleman RE. Indium-111 labelled platelets: studies on preparation and evaluation of in vitro and in vivo functions. Thromb Res 1976; 9: 345-357
• 20 ICSH Panel on diagnostic application of radioisotopes in haematology. Recommended methods for radioisotope platelet survival studies. Blood 1977; 50: 1137-1144
• 21 Lou HC, Nielsen JD, Bomholt A, Gormsen J. Platelet hyperaggrega- bility in young patients with completed stroke. Acta Neurol Scandinav 1977; 56: 326-334
• 22 Andersen LA, Gormsen J. Platelet aggregation and fibrinolytic activity in transient cerebral ischaemia. Acta Neurol Scand 1976; 55: 76-82
• 23 Zimmerman TS, Ratnoff OD, Powell AE. Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Wille- brand’s disease. J Clin Invest 1971; 50: 244-254
• 24 Scandinavian Standardizations of Enzyme Determination. Scand J Clin Lab Invest 1974; 33: 287-295
• 25 Gerhardt W, Waldenstrom J. Creatinekinase B-subunit activity in serum after immunoinhibition of M-subunit activity. Clin Chem 1979; 25: 1274-1282
• 26 Folts JD, Crowell Jr EB, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365-370
• 27 Vik-Mo H. Effects of acute myocardial ischaemia on platelet aggregation in the coronary sinus and aorta in dogs. Scand J Haematol 1977; 19: 68-74
• 28 Vik-Mo H. Platelet accumulation in the myocardium during acute nonthrombotic coronary artery occlusion in dogs. Scand J Haematol 1978; 21: 225-232
• 29 Ruf W, McNamara JJ, Suehiro A, Suehiro G. Platelet trapping in myocardial infarcts in baboons: Therapeutic effect of aspirin. Am J Cardiol 1980; 46: 405-412
• 30 Installé E, Gonzalez M, Schoevaerdts JC, Trémouroux J. Prevention by ticlopidine of platelet consumption during extracorporeal circulation for heart surgery and lack of effect on operative and postoperative bleeding. J Cardiovasc Pharmacol 1981; 3: 1174-1183
• 31 Maeda K, Usuda M, Kawaguchi S, Shinzato T, Saito A, Ohta K, Kobayashi K, Ohbayashi S. Effects of ticlopidine on thrombotic obstruction of A-V shunts and on dialysance of artificial kidneys. Artif Organs 1980; 4: 30-33
• 32 Ogawa S, Naruse T. Effects of various antiplatelet drugs and defibrinating agent on experimental glomerulonephritis in rats. J Lab Clin Med 1982; 99: 428-441
• 33 Abrahamsen AF. Platelet survival studies in man. Scand J Haematol 1968; 5 suppl (Suppl. 03) 1-86
• 34 Kaplan EJ, Saba TM. Platelet removal from the circulation by the liver and spleen. Am J Physiol 1978; 235: 314-320
• 35 Mustard JF. Platelet survival. Thromb Haemostas 1978; 40: 154-162